Smith BD - Search Results

1

Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia.

Lim Y, Gondek L, Li L, Wang Q, Ma H, Chang E, Huso DL, Foerster S, Marchionni L, McGovern K, Watkins DN, Peacock CD, Levis M, Smith BD, Merchant AA, Small D, Matsui W. Lim Y, et al. Among authors: smith bd. Sci Transl Med. 2015 Jun 10;7(291):291ra96. doi: 10.1126/scitranslmed.aaa5731. Sci Transl Med. 2015. PMID: 26062848 Free PMC article.

2

A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations.

Levis M, Tse KF, Smith BD, Garrett E, Small D. Levis M, et al. Among authors: smith bd. Blood. 2001 Aug 1;98(3):885-7. doi: 10.1182/blood.v98.3.885. Blood. 2001. PMID: 11468194 Free article.

3

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.

Levis M, Allebach J, Tse KF, Zheng R, Baldwin BR, Smith BD, Jones-Bolin S, Ruggeri B, Dionne C, Small D. Levis M, et al. Among authors: smith bd. Blood. 2002 Jun 1;99(11):3885-91. doi: 10.1182/blood.v99.11.3885. Blood. 2002. PMID: 12010785 Free article.

4

The role of growth factors in the activity of pharmacological differentiation agents.

Matsui WH, Gladstone DE, Vala MS, Barber JP, Brodsky RA, Smith BD, Jones RJ. Matsui WH, et al. Among authors: smith bd. Cell Growth Differ. 2002 Jun;13(6):275-83. Cell Growth Differ. 2002. PMID: 12114217

5

Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.

Tse KF, Allebach J, Levis M, Smith BD, Bohmer FD, Small D. Tse KF, et al. Among authors: smith bd. Leukemia. 2002 Oct;16(10):2027-36. doi: 10.1038/sj.leu.2402674. Leukemia. 2002. PMID: 12357354

6

Anti-tumour activity of interferon-alpha in multiple myeloma: role of interleukin 6 and tumor cell differentiation.

Matsui W, Huff CA, Vala M, Barber J, Smith BD, Jones RJ. Matsui W, et al. Among authors: smith bd. Br J Haematol. 2003 Apr;121(2):251-8. doi: 10.1046/j.1365-2141.2003.04255.x. Br J Haematol. 2003. PMID: 12694246 Free article.

7

Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay.

Murphy KM, Levis M, Hafez MJ, Geiger T, Cooper LC, Smith BD, Small D, Berg KD. Murphy KM, et al. Among authors: smith bd. J Mol Diagn. 2003 May;5(2):96-102. doi: 10.1016/S1525-1578(10)60458-8. J Mol Diagn. 2003. PMID: 12707374 Free PMC article.

8

Characterization of clonogenic multiple myeloma cells.

Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, Smith BD, Civin CI, Jones RJ. Matsui W, et al. Among authors: smith bd. Blood. 2004 Mar 15;103(6):2332-6. doi: 10.1182/blood-2003-09-3064. Epub 2003 Nov 20. Blood. 2004. PMID: 14630803 Free PMC article.

9

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K, Murphy KM, Dauses T, Allebach J, Small D. Smith BD, et al. Blood. 2004 May 15;103(10):3669-76. doi: 10.1182/blood-2003-11-3775. Epub 2004 Jan 15. Blood. 2004. PMID: 14726387 Free article. Clinical Trial.

10

Cancer stem cells: are we missing the target?

Jones RJ, Matsui WH, Smith BD. Jones RJ, et al. Among authors: smith bd. J Natl Cancer Inst. 2004 Apr 21;96(8):583-5. doi: 10.1093/jnci/djh095. J Natl Cancer Inst. 2004. PMID: 15100335 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,116 results

Search Page

Filters